| Document |
Document Title |
|
JP2664390B2 |
The invention relates to 11-aryl steroid derivatives, having the structure wherein: R1 is a homocyclic or heterocyclic aryl group having one of the following substituents: an optionally saturated or unsaturated, branched or unbranched hy...
|
|
JP2660413B2 |
Compounds (I): in which: R1 is hydrogen or methyl, R2 is methyl or ethyl, the nuclei A, B, C and D carry optionally one or more double bonds and are optionally substituted by one or more functional groups or by one or more atoms or radic...
|
|
JP2660404B2 |
1. The products of formula I : see diagramm : EP0245170,P90,F1 in which R1 represents an alkynyl radical having from 2 to 8 carbon atoms optionally substituted by a radical selected from the radicals, hydroxyl, halogen, trialkylsilyl, al...
|
|
JPH09509959A |
Compounds having a broad range of antimicrobial activity generally have a structure including a steroid nucleus with a cationic, preferably polyamine, side chain (X) and an anionic side chain (Y). The invention is also directed to compou...
|
|
JP2655676B2 |
The present invention is concerned with 11-aryloestrane and 11-arylpregnane derivatives, characterized in that these derivatives have the following structure: wherein R1 is an aryl group with an -N- @ group as substituent, X and Y each b...
|
|
JP2652007B2 |
PCT No. PCT/FR87/00096 Sec. 371 Date Nov. 25, 1987 Sec. 102(e) Date Nov. 25, 1987 PCT Filed Mar. 26, 1987 PCT Pub. No. WO87/05908 PCT Pub. Date Oct. 8, 1987. (I) (II) (III) (IV) (V) (VI) Products having the formula (I) wherein R1 is an a...
|
|
JPH09508896A |
PCT No. PCT/GB95/00065 Sec. 371 Date Oct. 4, 1996 Sec. 102(e) Date Oct. 4, 1996 PCT Filed Jan. 13, 1995 PCT Pub. No. WO95/19186 PCT Pub. Date Jul. 20, 1995The present invention relates to metabolically labile esters, and to contrast medi...
|
|
JP2649699B2 |
Pharmaceutical compositions for the prophylaxis and therapy of biliary tract calculosis and of biliary dyspepsia, containing as the active principle taurohyodeoxycholic acid, are herein described.
|
|
JP2648474B2 |
To obtain a novel compound consisting of a specific Ru complex containing a 2,2'-bipyridine compound as a ligand, emitting electromagnetic radiations, when receiving an electrochemical energy, and useful for analysis as an electrochemica...
|
|
JPH09508351A |
The invention relates to N-alkyl peptide chelate formers, their metal complexes with radionuclides, processes for their production and radio-pharmaceutical compositions containing these compounds. The invention also relates to radio-phar...
|
|
JP2642189B2 |
|
|
JP2642089B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2642090B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2636914B2 |
Antigestagens are useful for softening the nonpregnant cervix.
|
|
JP2612770B2 |
The present invention provides quaternary ammonium-substituted saponin ethers having improved electrostatic and hydrophobic interactive activities, and therefore very useful in hair-care and skin-care products. The product of the inventi...
|
|
JPH09504553A |
Compounds of formula (I) are inhibitors of 5 alpha -reductase and are useful alone or in combination with 5 alpha -reductase 1 and/or 2 inhibitors for the treatment of hyperandrogenic disorders such as acne vulgaris, seborrhea, female hi...
|
|
JPH09118687A |
PURPOSE: To profitably and easily obtain a pharmaceutically useful steroid by a method using a new production intermediate. CONSTITUTION: This method for producing a 17α-hydroxy-20-oxopregnane derivative comprises converting a steroid d...
|
|
JP2599606B2 |
A compound of the formula I wherein R1 is hydrogen or methyl, R2 is methyl or ethyl, the A,B,C and D rings optionally have one or more double bonds and are optionally substituted with one or more members of the group consisting of haloge...
|
|
JPH09503228A |
The present invention provides a compound of formula (I), wherein A is a bond or a straight or branched C1-C6 alkylene chain; W is a group -R1, -OR2, -NR3R4 or (a) wherein: Y is oxygen or sulphur; R1, R2 and R4 are: a C1-C10 alkyl group,...
|
|
JPH09502984A |
Urethane-containing amino steroids having the general chemical formula: wherein a, b, R1, R2, R3, R4, R14 and Z are as defined in the specification. Also disclosed are pharmaceutical composition and the use of the compounds/composition i...
|
|
JPH09502982A |
The present invention relates to oligosaccharide-containing 14-aminosteroid compounds and the pharmaceutically-acceptable acid salts or esters thereof of the general formula: wherein a) R1 is (i) COOR5, where R5 is hydrogen, a 1-6 carbon...
|
|
JPH09502983A |
Disclosed are 14-aminosteroid compounds, including pharmaceutically acceptable acid salts and esters thereof, useful in treating individuals afflicted with congestive heart failure, which compounds have the general formula: wherein R3 is...
|
|
JP2588267B2 |
New 19,11 beta -bridged steroids of the general formula I (I) where R1 stands for a methyl or ethyl radical, R2 for a hydrogen or chlorine atom or a C1-C4-alkyl radical, B and G, which are the same or different, respectively for a hydrog...
|
|
JP2584829B2 |
9(11)-dehydroandrostanes and 9(11)-dehydropregnanes are prepared by dehydrating the corresponding 9-alpha-hydroxy steroid in the presence of a Lewis acid. The corresponding 8(9)-dehydro-isomer was not detectable. The resulting products a...
|
|
JP2582088B2 |
Antigestagens are used to produce drugs for inhibiting terine prostaglandin synthesis.
|
|
JPH09501433A |
The applications discloses the treatment of inflammatory disorders, in particular those associated with rheumatoid, arthritis, gout, gouty arthritis and Behcet's syndrome, with 2-methoxyestradiol.
|
|
JPH0912593A |
To obtain the new derivatives comprising a specific 17- hydroxyiminoalkylcyclopentane perhydrophenanthrene derivative, etc., having affinity to Na+, K+-ATPase receptors, and useful for the therapy of cardiac failures, hypertension, etc. ...
|
|
JP2568306B2 |
Bile acid derivatives of the formula I W-X-G in which G is a bile acid residue, W is an active substance portion of a medicament and X is a linker between bile acid residue and active substance portion, are outstandingly suitable for int...
|
|
JP2566574B2 |
A compound of the formula: useful as cancer preventive agent, anti-obesity agent, anti-hyperglycemic agent, anti-aging agent and anti-hypercholesterolemic agent and useful in combatting coronary diseases and autoimmune diseases. Encompas...
|
|
JPH08333398A |
To obtain an antibody requiring neither extraction nor chromatography in an immunoassay process for cortisol by immunization of animals against the hapten cortisol-3-carboxymethyloxime (syn isomer) coupled to a macromolecule. This antibo...
|
|
JP2562134B2 |
Novel platinum(II)-steroid complexes are now provided, which exhibit antitumor activities as shown by tests on mouse leukemia, L-1210 cells in mice. These novel platinum(II)-steroid complexes contain a 1,2-cyclohexanediamine, a 2-(aminom...
|
|
JP2563587B2 |
The present invention concerns novel compounds having the general formula wherein R<1>, R<2> and R<3> are selected from the group consisting of hydrogen or lower alkyl having 1-4 carbon atoms, wherein R<2> and R<3> together with the N at...
|
|
JP2560370B2 |
|
|
JP2558491B2 |
|
|
JP2554005B2 |
PURPOSE: To extremely easily obtain estramustine phosphate having high purity with a simple operation. CONSTITUTION: Crude estramustine phosphate can be purified by dissolving the crude substance in a fatty acid ester, adding methanol (o...
|
|
JP2554006B2 |
PURPOSE: To surely acylate phenolic hydroxyl group at the 3-position of estradiol. CONSTITUTION: This method for selectively acylating estradiol is characterized by selectively introducing an N-bis(2-chloroethyl)carbamoyl halogenide into...
|
|
JPH08510733A |
This invention is directed to 4-amino-17 beta -(cyclopropyloxy)androst-4-en-3-one, 4-amino-17 beta -(cyclopropylylamino)androst-4-en-3-one and related compounds, a process for their synthesis, a pharmaceutical composition having C17-20 l...
|
|
JP2550777B2 |
|
|
JPH08510452A |
Unsubstituted or substituted halo nitro and nitroso compounds and their metabolites are potent, selective and non-toxic inhibitors and supressants of cancer growth and viral infections in a mammalian host. The compounds are particularly ...
|
|
JP2549721B2 |
17 beta -Cyano-17 alpha -hydroxy steroids (I) are transformed to 17 alpha -halo silyl ethers (II) which are intermediates useful in the production of progesterones (V), 17-hydroxyprogesterones (VI), corticoids (VII) and 21-halo corticoid...
|
|
JP2549724B2 |
Amine salts of alkane-1,n-dicarboxylic acid mono-(2-sulfato-ethyl)amides of the formula (I): HOC(O)-(CH2)n-C(O)-N(R1)-CH2CH2SO3 <-> <+> HN(R2)3, wherein R1 is selected from the group consisting of hydrogen, C1-C8 alkyl and phenyl, R2 is ...
|
|
JP2545522B2 |
This invention provides novel tetrahydro steroids which are useful in inhibiting angiogenesis and have the following structure: A compound of the formula: wherein R1 is beta -CH3 or beta -CH2H5; wherein R2 is H, and R3 is =0, -OH, -0-alk...
|
|
JPH08245687A |
PURPOSE: To obtain the subject new compound which is an N-substituted carbamide derivative of 3-carboxy-androst-3,5-diene and useful for treatment, etc., of acne, seborrhoica, hirsutism, alopecia, etc., as a testosterone 5α-reductase in...
|
|
JPH08508727A |
PCT No. PCT/EP94/00937 Sec. 371 Date Oct. 6, 1995 Sec. 102(e) Date Oct. 6, 1995 PCT Filed Mar. 24, 1994 PCT Pub. No. WO94/22898 PCT Pub. Date Oct. 13, 1994Glucocorticoids of general formula IR-Val-O-GC (II),are described, in which O-GC i...
|
|
JPH08508506A |
PCT No. PCT/DE94/00316 Sec. 371 Date Nov. 6, 1995 Sec. 102(e) Date Nov. 6, 1995 PCT Filed Mar. 18, 1994 PCT Pub. No. WO94/24146 PCT Pub. Date Oct. 27, 1994Novel androgens having one or more substituents providing radical trapping propert...
|
|
JPH08225590A |
To obtain the subject new compound, a specific steroid with a 17- spiromethylene lactone group or the like, with low affinity for a progesterone receptor and slight side effects, and usable as a contraceptive, or in treating menstrual di...
|
|
JP2525049B2 |
|
|
JP2520403B2 |
Essentially organic, non-metallic ribbon useful as a twist tie comprising polymeric material exhibiting glass/rubber transitional behavior. Polymeric ribbons deformed under tensile stress at 25 exhibit yield stress between about 500 and ...
|
|
JP2520074B2 |
PURPOSE: To provide a new compound having remarkably improved utility as an antitumor agent and immunosuppressing agent by eliminating or decreasing an estragen action while keeping selective antitumor action and immunosuppressing action...
|
|
JPH08506589A |
Invented are compositions of competitive and uncompetitive inhibitors of steroid 5- alpha -reductase, pharmaceutical compositions containing the compositions of inhibitors and methods of using these compositions to inhibit steroid 5- alp...
|
